• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is Omeros (OMER) Undervalued After The EMA Upheld Its Narsoplimab Setback?

    Simply Wall St·10/17/2026 10:29:36
    語音播報

    Omeros (OMER) is back in focus after the European Medicines Agency’s Committee for Medicinal Products for Human Use upheld a negative opinion on narsoplimab for TA-TMA, which prompted a sharp share-price reaction.

    The EMA setback has triggered a sharp short-term reset, with the share price down 13.78% in the last day and 18.31% over the week. Yet Omeros still carries a 99.88% 1-year total shareholder return and a very large 3-year total shareholder return, so recent selling reflects a swing in sentiment and perceived regulatory risk rather than a simple reversal of the longer-run momentum.

    Spot shifting sentiment around Omeros, and compare it with 33 high quality undervalued stocks, which have been hand picked for strong fundamentals and potential mispricing.

    Bulls point to Omeros’ FDA approved YARTEMLEA and hefty 1 year return, while bears point to Europe’s pushback and execution risk. Which side does the current valuation actually support?

    Most Popular Narrative: 41% Undervalued

    Against Omeros' last close of $16.20, the most followed narrative anchors fair value at $27.50, which implies a large valuation gap that hinges on how investors view cash inflows and the complement pipeline.

    The expected closing of the Novo Nordisk transaction, with US$240 million upfront and up to US$2.1 billion in total potential consideration plus royalties, would remove near term debt obligations and extend the cash runway. This could ease funding risk and support future revenue and earnings growth from the remaining pipeline.

    See why 3 investors see Omeros as 41% undervalued.

    Result: Fair Value of $27.50 (UNDERVALUED)

    Still, the narrative can unravel quickly if the Novo Nordisk cash inflow is delayed, or if YARTEMLEA faces tougher than expected regulatory outcomes.

    Find out about the key risks to this Omeros narrative.

    Next Steps

    Sentiment around Omeros is split, with sharp recent moves contrasting with strong trailing returns and a live mix of concern and optimism. Act quickly, review the full picture, and weigh both the upside and the warning flags through 4 key rewards and 4 important warning signs.

    Looking for more investment ideas beyond Omeros?

    You have seen how quickly sentiment can swing around Omeros. Do not stop here. Broaden your watchlist with other opportunities that fit your style.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.